“Patient-centered treatment” for mild-to-moderate psoriasis

References

• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–81
   PubMed Web of Science ®Google Scholar
• Nast A, Spuls PH, Ormerod AD, et al. A critical appraisal of evidence based guidelines for the treatment of psoriasis vulgaris: AGREE-ing on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2009;23:782–7
   PubMed Web of Science ®Google Scholar
• Nash AS, McAteer H, Schofield J, et al. Psoriasis today: experiences of healthcare and impact on quality of life in a major UK cohort. Prim Health Care Res Dev 2014;5:1–9
   Google Scholar
• Nelson PA, Barker Z, Griffiths CE, et al. Impact team. On the surface: a quality study of GP s and patient perspectives on psoriasis. BMC Fam Pract. 2013;14:158
   PubMed Web of Science ®Google Scholar
• Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures and necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45:72–6
   PubMed Web of Science ®Google Scholar
• Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12:667–82
   PubMed Web of Science ®Google Scholar
• Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology. 1994;189:260–4
   PubMed Web of Science ®Google Scholar
• Poyner T, Hughes IW, Dass H. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatolog Treat. 1993;4:173–6
   Google Scholar
• Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144:17–9
   PubMed Web of Science ®Google Scholar
• Langner A, Ashton P, Van De Kerkhof PC, Verjans H. A long-term multicentre assessment of the safety and ointment in the treatment of chronic plaque psoriasis tolerability of calcitriol. Br J Dermatol. 1996;135:385–9
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol. 2002;146:414–22
   PubMed Web of Science ®Google Scholar
• Cornell RC, Stoughton RB. Six-months controlled study of effect of desoxymethasone and betamethasone 17-valerate on the pituitary-adrenal axis. Br J Dermatol. 1981;105:91–5
   PubMed Web of Science ®Google Scholar
• Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183:269–74
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management of psoriasis with topical treatments. J Am Acad Dermatol. 2011;65:137–74
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48–54
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes J, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet_/Daivobet_/Taclonex_) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154:1155–60
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet_ /Dovobet_ /Taclonex) in the treatment of psoriasis vulgaris. Dermatology. 2006;213:319–26
   PubMed Web of Science ®Google Scholar
• Mason A, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol. 2013;69:799–807
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Mul K, Oostveen AM, et al. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171:363–9
   Google Scholar
• Storm A, Benfeldt E, Andersen S E, Serup J A. Prospective study of patient adherence to topical; treatments. J Am Acad Dermatol. 2008;59:975–80
   PubMed Web of Science ®Google Scholar
• Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–16
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for non-adherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55:607–13
   PubMed Web of Science ®Google Scholar
• Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81–3
   PubMed Web of Science ®Google Scholar
• Zschocke I, Mrowietz U, Lotzin A, et al. Assessing adherence factors in patients under topical treatment, development of the topical therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res. 2014;306:287–97
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke M. Health economic issues in psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2014;14:559–68
   PubMed Web of Science ®Google Scholar
• Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71:1167–75
   PubMed Web of Science ®Google Scholar
• Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304:433–41
   PubMed Web of Science ®Google Scholar
• Saraceno R, Camplone G, D’Agostino M, et al. Efficacy and maintenance strategies of two compound formulation calcipotriol and betamethasone diproprionate gel (xamiol gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25:30–3
   PubMed Web of Science ®Google Scholar